Company: MDCXW
Filing Date: 2025-09-02
Form Type: 424B3
Source: 0001062993-25-015158
Chunk: 3

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-02
Form: 424B3
Chunk 3
---
 provided by each of Regulation S under the Securities Act and Section 4(a)(2) thereof.

As further described in the Definitive Agreement, the Consideration Shares issued to the Antev Vendors are subject to the following staggered lock-up restrictions: (i) 15% of the Consideration Shares will be automatically released on the day that is 30 days after the initial registration statement registering the resale of the Consideration Shares (the "Registration Statement") is declared effective by the United States Securities and Exchange Commission (the "SEC"), (ii) 15% of the Consideration Shares will be automatically released on the day that is 60 days after the Registration Statement is declared effective by the SEC, (iii) 15% of the Consideration Shares will be automatically released on the day that is 90 days after the Registration Statement is declared effective by the SEC, (iv) 15% of the Consideration Shares will be automatically released on the day that is 120 days after the Registration Statement is declared effective by the SEC, (v) 15% of the Consideration Shares will be automatically released on the day that is 150 days after the Registration Statement is declared effective by the SEC, (vi) 15% of the Consideration Shares will be automatically released on the day that is 180 days after the Registration Statement is declared effective by the SEC, and (vii) 10% of the Consideration Shares will be automatically released on the day that is 210 days after the Registration Statement is declared effective by the SEC; provided that any Consideration Shares that have not been released from the lock-up restriction in accordance with the foregoing on or before the nine-month anniversary of the Closing date shall be automatically released on such date.

In addition, on August 27, 2025 and September 2, 2025, pursuant to the previously disclosed Standby Equity Purchase Agreement (the "SEPA"), dated February 10, 2025, between the Company and YA II PN, Ltd. ("Yorkville"), the Company sold 100,000 of its common shares (the "Common Shares") to Yorkville for $2.0396 per share, or $203,960 in consideration and 150,000 Common Shares to Yorkville for $1.9105 per share, or $286,575 in consideration, respectively (together, the "SEPA Advances"). The Company sold, in the aggregate, 250,000 Common Shares to Yorkville through the SEPA Advances and